Brief: Obseva: Positive Results From Two Phase 3 Studies Of Yselty® (Linzagolix)
06/07/2020 06:13
July 6 (Reuters) - OBSEVA SA OBSN.S :
* ANNOUNCES POSITIVE RESULTS FROM TWO PHASE 3 STUDIES,
PRIMROSE 1
AND 2, OF YSELTY® (LINZAGOLIX) FOR TREATMENT OF UTERINE FIBROIDS
Source text for Eikon: ID:nGNEbls0g2
Further company coverage: OBSN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary